The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial

The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial

Abstract Background Fibromyalgia is a chronic multidimensional pain disease with no curative treatment currently available. Its management relies on a multimodal approach involving pharmacologic and non-pharmacologic elements. Because a suggested factor in its etiology is a central sensitization phe...

Full description

Bibliographic Details
Main Authors: Zuzana Javorcikova, Michel Dangoisse, Stéphane Nikis, Jean-Paul Lechat, Aline Gillain, Jean-François Fils, Philippe Van der Linden
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Trials
Subjects:
S-ketamine
Fibromyalgia
Chronic pain
Treatment
N-Methyl-D-aspartate receptor
Online Access:https://doi.org/10.1186/s13063-021-05814-4

Internet

https://doi.org/10.1186/s13063-021-05814-4

Similar Items